First 90 Days

A biopharma bolsters patient centricity and trial diversity goals through newly created role

Against the backdrop of the industry generally avoiding DEI topics, Ardelyx continues to strengthen its commitment to patient-centricity and clinical trial diversity by creating the new Chief Patient Officer position. New Chief Patient Officer Dr. Laura Williams shared participation data of 45% Black and 28% Hispanic patients in the company's dialysis patient trials, and elaborated on how strategic initiatives embed patient experience into all stages of drug development, approval, and commercialization.